For example, FL and DLBCL patients carrying EZH2 mutations identified in lymphoma tissue or ctDNA show a better response to the EZH2 inhibitor tazemetostat than patients with wildtype EZH2 [92, 93]. This evidence concerns the gene EZH2 and lymphoma.